U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07661056) titled 'Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease' on June 16.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Graves Disease
Intervention:
DRUG: BHV-1300
delivered subcutaneously via autoinjector
DRUG: Placebo
delivered subcutaneously via autoinjector
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Biohaven Therapeutics Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....